First quarter 2018 results of 11 major European pharmaceutical companies

F. Hoffmann-La Roche Ltd. released first-quarter results. Group sales for the quarter were CHF 13.583 billion, compared with CHF 12,942 million a year earlier. Of this total, the pharmaceutical business had sales of CHF 10,672 million in the quarter, compared with CHF 10,177 million a year earlier. The diagnostics business had sales of CHF 2,911 million in the quarter, compared with CHF 2,765 million a year earlier.
Novartis AG, the company's financial report. The company's first-quarter net sales were $12.694 billion, compared with $11.539 billion a year earlier. Net profit for the quarter was $2,028 million, compared with $1,665 million a year earlier.Sanofi SA's first-quarter results. Net sales for the quarter were EUR 7,898 million, compared with EUR 8.653 billion a year earlier. Sanofi completed its acquisition of Bioverativ in the first quarter. Net profit for the quarter was EUR 1,016 million, compared with EUR 5.696 billion a year earlier.(GSK) reported sales of ￡7.2bn in the first quarter of 2018, down 2 per cent on the basis of real exchange rates and 4 per cent on a constant exchange rate. Sales of prescription drugs are 4 billion pounds, vaccine sales are 1.2 billion pounds, and consumer health products are 2 billion pounds.AstraZeneca PLC reported first-quarter 2018 results. Total revenue for the quarter was $5,178 million, down 9% from a year earlier. Operating profit was $896 million, down 47% from a year earlier.sales increased in the first three months of 2018 from Bayer. In the first quarter, the Group's sales rose 2.0 per cent (adjusted for a 5.6 per cent decline in exchange rates and portfolios) to EUR 9,138 million. Profit before interest, tax, depreciation and amortization, net of special items, fell 5.2 per cent to EUR 2,896 million. EST fell 4.8 per cent to 2.310 billion euros. Net income fell 6.2 per cent to 1,954 million euros. Sales of prescription drugs amounted to EUR 4,075 million, sales of self-care products (health consumer goods) amounted to EUR 1,409 million, sales of agricultural business (crop science division) amounted to EUR 2,861 million and sales of animal health business amounted to EUR 414 million. , Germany's Merck KGaA, reported first-quarter results for 2018. Net sales for the quarter were EUR 3,691 million, down 4.4% from EUR 3,861 million a year earlier. EBITDA profit for the quarter was EUR 946 million, down 21.4% from EUR 1.203 billion a year earlier. Net sales of 1.640 billion euros in the health business, 1.487 billion euros in the life sciences business and 564 million euros in the materials business.
allergan narrowed its first-quarter net loss to $332.5 million, compared with $2.63 billion a year earlier. Revenue rose 2.8 percent to $3.67 billion, with better-than-expected international brand revenue offsetting a smaller-than-expected U.S. professional treatment revenue, while U.S. regular drug revenue was in line with expectations.
Shire plc reported first-quarter results for 2018. Total revenue for the quarter was $3.766 billion, up 5% year-on-year. Net profit for the quarter was $551 million, up 47% year-on-year.Mylan said first-quarter earnings rose to $87.1 million, compared with $66.4 million a year earlier. Revenue fell to $2.68 billion from $2.72 billion. Net sales in North America fell year-on-year, with sales of branded products such as epiPen falling significantly.Nordisk to report first-quarter 2018 results. Sales fell 5 percent to DKK 26.9 billion in DKK. Sales in the area of diabetes treatment and obesity fell 5 per cent to DKK 22.6 billion. Sales in the biopharmaceutical sector fell 8 per cent to DKK 4.3 billion. Operating profit reported in DKK decreased by 8% to DKK 12.4 billion. Net profit rose 6 per cent to DKK 10.8 billion. (Global Enterprise Dynamics)